Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04612166 · ClinicalTrials.gov registry record · NA

Medication Empowerment and Deprescription for Safety (MEDS) Study

A NA study, sponsored by University of Iowa.

Completed
Registry status
NA
Development phase
398
Enrollment target

NCT04612166: Completed NA study, sponsored by University of Iowa.

NCT04612166 is a NA study that has completed, run by University of Iowa. The registered enrollment target is 398 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04612166, a NA study, has completed, sponsored by University of Iowa.

COMPLETED
Registry status
NA
Development phase
398 participants
Enrollment target

Study Summary

The long-term goal of this pragmatic, cluster randomized study is to develop a sustainable program for healthcare systems to reduce fatal and nonfatal falls among high-risk older adults living independently in their communities. This study will examine how a medication care plan, grounded in established medication deprescribing and tapering frameworks, can be implemented in primary care clinics to reduce falls among older adults living in rural Iowa communities. The study is a collaboration between researchers and clinical pharmacists at the University of Iowa and a clinical team from the MercyOneSM Health Network, which is a non-academic healthcare system with significant reach into rural Iowa communities The study's specific goals are as followed: * Aim 1: Examine the effectiveness of a clinic-based, individualized medication care plan in reducing rates of all falls including medically treated falls (sub-aim 1a) and motor vehicle charges and crashes (sub-aim 1b) among older adults seen in rural primary care clinics. * Aim 2: Identify provider and patient factors that are associated with patient adherence to medication deprescribing and discontinuation recommendations. * Aim 3\*: Evaluate implementation of the medication care plan to understand its acceptability, usability and relevance among healthcare system administrators, clinics (clinic managers and clinical staff), providers (health coaches, pharmacists, prescribers) and participants. Note\*: Only Aims 1 and 2 (i.e., pertinent to the clinical trial) will be described in this clinicaltrials.gov study description. Intervention and control participants will participate in: * Baseline assessment * Quarterly follow-up assessments * Monthly falls tracking Additionally, intervention participants will receive: • An individualized medication action plan to deprescribe medications that put them at high risk for a fall Researchers will compare intervention and control participants for changes in self-reported fa

Primary Outcome

Self-reported measure of the number of times the participant experienced a fall each month using a falls calendar. The participant will document each fall and whether the fall resulted in medical treatment, such as hospitalization, an emergency department visit, and/or a visit to their physician or other healthcare provider. The investigators will compare frequency between intervention and control groups.

Interventions

  • BEHAVIORAL Medication Action Plan and Patient Empowerment (MAP-PE )

Trial Details

FieldValue
Enrollment Target 398 participants
Start Date 2020-08-01
Est. Completion 2024-06-30
Phase NA
University of Iowa

228 total trials

What the finished NCT04612166 record still lists

NCT04612166 is an interventional study that assigns participants to a tested intervention. The registered 398 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 1 intervention - of which Medication Action Plan and Patient Empowerment (MAP-PE ) is the first listed.

NCT04612166 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04612166 about?

NCT04612166 is a clinical study titled "Medication Empowerment and Deprescription for Safety (MEDS) Study". The long-term goal of this pragmatic, cluster randomized study is to develop a sustainable program for healthcare systems to reduce fatal and nonfatal falls among high-risk older adults living independently in their communities. This study will examine how a medication care plan, grounded in establi...

What is the current status of trial NCT04612166?

This trial is currently completed. It is a NA study. The enrollment target is 398 participants. The study started on 2020-08-01. Estimated completion is 2024-06-30.

What interventions are being tested in trial NCT04612166?

The interventions under investigation include: Medication Action Plan and Patient Empowerment (MAP-PE ) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04612166?

This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04612166's enrollment target sits among peer trials

398 267th of 2000 higher than 1,734 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05365581 · 398 participants · Phase 1

    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

  • NCT03165734 · 399 participants · Phase 3

    A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  • NCT05022862 · 399 participants · NA

    Economic Incentives and vDOT for Latent Tuberculosis Infection

  • NCT00601939 · 397 participants · NA

    Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04612166, the US trial registry maintained by the National Library of Medicine. NCT04612166 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.